Vedolizumab is a humanized monoclonal antibody targeting α4β7 integrin, approved by the U.S. FDA in May 2014 for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD) who have had an inadequate response, loss of response, or intolerance to conventional therapy or a TNF-α antagonist; it is also used in research related to ulcerative colitis and Crohn's disease.